A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

Cardiovascular disease is a general term that refers to many different types of heart problems.Heart disease is the ...

In recent years, the rate of cardiovascular mortality following high-risk myocardial infarction has significantly declined.

De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary ...

A KAIST research team led by Professor Keon Jae Lee has proposed an innovative theoretical framework and research strategies ...

Diabetes mellitus type 1 (DM1) is associated with lower probability of incident cardiovascular events than type 2 (DM2).

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.